Achmea Funding Administration B.V. lifted its holdings in Johnson & Johnson (NYSE:JNJ – Free Report) by 8.0% within the second quarter, in line with its most up-to-date disclosure with the Securities & Change Fee. The fund owned 219,746 shares of the corporate’s inventory after shopping for a further 16,340 shares throughout the quarter. Achmea Funding Administration B.V.’s holdings in Johnson & Johnson had been value $32,118,000 on the finish of the latest quarter.
A number of different institutional traders and hedge funds have additionally added to or lowered their stakes within the inventory. Meridian Monetary Companions LLC purchased a brand new stake in shares of Johnson & Johnson throughout the second quarter value $1,626,000. Summit Monetary Wealth Advisors LLC raised its holdings in Johnson & Johnson by 26.3% throughout the 1st quarter. Summit Monetary Wealth Advisors LLC now owns 5,392 shares of the corporate’s inventory value $853,000 after buying a further 1,122 shares over the last quarter. Gilbert & Prepare dinner Inc. lifted its place in Johnson & Johnson by 3.3% throughout the 4th quarter. Gilbert & Prepare dinner Inc. now owns 9,111 shares of the corporate’s inventory valued at $1,428,000 after buying a further 288 shares throughout the interval. Franklin Parlapiano Turner & Welch LLC boosted its stake in shares of Johnson & Johnson by 0.7% within the 1st quarter. Franklin Parlapiano Turner & Welch LLC now owns 47,186 shares of the corporate’s inventory valued at $7,464,000 after buying a further 325 shares over the last quarter. Lastly, Capital Asset Advisory Providers LLC raised its stake in shares of Johnson & Johnson by 8.8% throughout the first quarter. Capital Asset Advisory Providers LLC now owns 26,539 shares of the corporate’s inventory value $4,044,000 after shopping for a further 2,151 shares over the last quarter. Institutional traders and hedge funds personal 69.55% of the corporate’s inventory.
Johnson & Johnson Inventory Up 0.5 %
Shares of JNJ inventory opened at $165.52 on Friday. Johnson & Johnson has a 12-month low of $143.13 and a 12-month excessive of $168.85. The corporate has a fast ratio of 0.85, a present ratio of 1.07 and a debt-to-equity ratio of 0.44. The agency has a fifty day transferring common of $159.55 and a 200-day transferring common of $154.04. The corporate has a market capitalization of $398.45 billion, a price-to-earnings ratio of 10.32, a P/E/G ratio of two.71 and a beta of 0.53.
Johnson & Johnson (NYSE:JNJ – Get Free Report) final launched its earnings outcomes on Wednesday, July seventeenth. The corporate reported $2.82 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.71 by $0.11. The agency had income of $22.45 billion throughout the quarter, in comparison with analysts’ expectations of $22.33 billion. Johnson & Johnson had a return on fairness of 36.60% and a web margin of 46.34%. The corporate’s income was up 4.3% on a year-over-year foundation. Throughout the identical quarter within the prior 12 months, the corporate earned $2.80 EPS. As a gaggle, equities analysis analysts predict that Johnson & Johnson will put up 10.02 earnings per share for the present fiscal 12 months.
Johnson & Johnson Dividend Announcement
The corporate additionally just lately introduced a quarterly dividend, which was paid on Tuesday, September tenth. Shareholders of document on Tuesday, August twenty seventh had been paid a $1.24 dividend. This represents a $4.96 annualized dividend and a yield of three.00%. The ex-dividend date of this dividend was Tuesday, August twenty seventh. Johnson & Johnson’s payout ratio is 30.92%.
Analysts Set New Worth Targets
Quite a few equities analysts have issued experiences on JNJ shares. The Goldman Sachs Group lowered their worth goal on shares of Johnson & Johnson from $160.00 to $155.00 and set a “impartial” ranking on the inventory in a analysis word on Friday, July nineteenth. Daiwa Capital Markets lowered Johnson & Johnson from an “outperform” ranking to a “impartial” ranking and lowered their worth goal for the inventory from $160.00 to $150.00 in a analysis report on Tuesday, July twenty third. Royal Financial institution of Canada reiterated an “outperform” ranking and issued a $175.00 worth goal on shares of Johnson & Johnson in a report on Tuesday, July thirtieth. TD Cowen lower their goal worth on Johnson & Johnson from $195.00 to $185.00 and set a “purchase” ranking on the inventory in a analysis word on Thursday, July 18th. Lastly, StockNews.com upgraded Johnson & Johnson from a “purchase” ranking to a “strong-buy” ranking in a analysis report on Saturday. Seven equities analysis analysts have rated the inventory with a maintain ranking, six have issued a purchase ranking and one has assigned a robust purchase ranking to the inventory. Based mostly on knowledge from MarketBeat, the corporate presently has a mean ranking of “Reasonable Purchase” and a mean worth goal of $173.21.
View Our Newest Evaluation on JNJ
Insider Transactions at Johnson & Johnson
In different information, VP Robert J. Decker offered 5,635 shares of the enterprise’s inventory in a transaction on Friday, August thirtieth. The shares had been offered at a mean worth of $165.06, for a complete worth of $930,113.10. Following the sale, the vp now owns 18,973 shares of the corporate’s inventory, valued at $3,131,683.38. The sale was disclosed in a authorized submitting with the SEC, which is accessible by means of the SEC web site. Firm insiders personal 0.16% of the corporate’s inventory.
About Johnson & Johnson
Johnson & Johnson, along with its subsidiaries, researches, develops, manufactures, and sells numerous merchandise within the healthcare discipline worldwide. The corporate’s Revolutionary Drugs section gives merchandise for numerous therapeutic areas, similar to immunology, together with rheumatoid arthritis, psoriatic arthritis, inflammatory bowel illness, and psoriasis; infectious illnesses comprising HIV/AIDS; neuroscience, consisting of temper issues, neurodegenerative issues, and schizophrenia; oncology, similar to prostate most cancers, hematologic malignancies, lung most cancers, and bladder most cancers; cardiovascular and metabolism, together with thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension by means of retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.
Learn Extra
Obtain Information & Rankings for Johnson & Johnson Every day – Enter your e-mail tackle beneath to obtain a concise each day abstract of the newest information and analysts’ rankings for Johnson & Johnson and associated corporations with MarketBeat.com’s FREE each day e-mail e-newsletter.
